Goldman Sachs
AGN.PRA

Goldman Sachs’s Allergan plc AGN.PRA Stock Holding History

Goldman Sachs’s Portfolio AGN.PRA Stock Details AGN.PRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-22,369
Closed -$13.1M – 6663
2017
Q4 		$13.1M Sell
22,369
-8,450
-27% -$5.45M ﹤0.01% 2249
2017
Q3 		$22.7M Buy
30,819
+4,493
+17% +$3.73M 0.01% 1873
2017
Q2 		$22.8M Buy
26,326
+3,774
+17% +$3.16M 0.01% 1822
2017
Q1 		$19.1M Buy
22,552
+2,903
+15% +$2.41M 0.01% 1914
2016
Q4 		$15M Buy
19,649
+19,202
+4,296% +$14.5M ﹤0.01% 2167
2016
Q3 		$367K Sell
447
-9,766
-96% -$8.44M ﹤0.01% 5325
2016
Q2 		$8.51M Buy
10,213
+2,826
+38% +$2.36M ﹤0.01% 2434
2016
Q1 		$6.79M Sell
7,387
-613
-8% -$586K ﹤0.01% 2511
2015
Q4 		$8.23M Buy
8,000
+3,500
+78% +$3.52M ﹤0.01% 2405
2015
Q3 		$4.25M Sell
4,500
-11,252
-71% -$11.7M ﹤0.01% 3026
2015
Q2 		$16.5M Buy
+15,752
New +$16.5M 0.01% 1936

Other funds holding AGN.PRA

PWS
Peloton Wealth Strategists Indianapolis, Indiana $271M AUM 19.14% 1-Year Est. Return

Goldman Sachs's AGN.PRA Position: Q1 2018 in Review

Goldman Sachs sold out of Allergan plc (AGN.PRA) in Q1 2018, closing a stake of 22,369 shares — an estimated $13.1M sold.

Goldman Sachs first reported a position in AGN.PRA in Q2 2015 and held it in 11 quarters. The position peaked at $22.8M in Q2 2017. 1 fund tracked by Wall St. Rank holds AGN.PRA as of Q1 2018.

  • Goldman Sachs reported no remaining Allergan plc position as of Q1 2018 after selling out during the quarter.
  • Goldman Sachs sold 22,369 Allergan plc shares in Q1 2018, an estimated $13.1M.
  • Goldman Sachs first reported a position in Allergan plc in Q2 2015 and held it in 11 quarters.
  • Goldman Sachs's Allergan plc position peaked at $22.8M in Q2 2017.
  • 1 fund tracked by Wall St. Rank held Allergan plc as of Q1 2018.

Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.